tiprankstipranks
‘Lots to like’ about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald
The Fly

‘Lots to like’ about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen reiterated the firm’s Overweight rating or $15 price target on shares of Scynexis (SCYX) following the "good" Q4 and announcement of a deal with GSK (GSK). The firm sees "lots to like" and continues to think that the peak sales potential of ibrexafungerp for the treatment of fungal infections is underappreciated and also expects upwards earnings estimate revisions to drive Scynexis shares higher as earnings visibility for the company improves, the analyst tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SCYX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles